# Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)

> **NCT04975256** · PHASE1 · TERMINATED · sponsor: **Mirati Therapeutics Inc.** · enrollment: 7 (actual)

## Conditions studied

- Advanced Cancer
- Metastatic Cancer
- Malignant Neoplasm of Colon
- Malignant Neoplasm of Lung
- Malignant Neoplastic Disease

## Interventions

- **DRUG:** MRTX849
- **DRUG:** BI 1701963

## Key facts

- **NCT ID:** NCT04975256
- **Lead sponsor:** Mirati Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-07-28
- **Primary completion:** 2022-11-02
- **Final completion:** 2022-11-15
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** The decision was made to terminate this study to further enrollment, as of 08 March 2022. The decision was made primarily due to a change in development strategy.
- **Last updated:** 2024-12-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04975256

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04975256, "Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04975256. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*